Opinion: NEJM sheds light on payments to doctors
It should come as no surprise that pharmaceutical companies pay doctors for a variety of reasons such as research, lecturing, and teaching. Such payments are justified as these physicians tend to be in demand as experts and their expertise is valued. They can't be expected to do this work pro bono – their time is valuable. However, such payments are viewed with great suspicion. Industry critics are quick to charge that what companies are really doing is currying favor with doctors so that they will write more prescriptions for their drugs. This type of "manipulation" is believed to be a conflict-of-interest.
- NFP Hospitals' Revenue Growth at 'All-Time Low'
- Interventional Radiology No Longer a Sub-Specialty
- Acute Kidney Injury Gets New Focus
- Transforming Cancer Care
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013
- mHealth Tackles Readmissions
- CNO Leads $1M Charge for New Scrubs, Uniforms
- Sharp HealthCare Leaves Pioneer ACO Program
- MA an Insurance Proving Ground for Providers
- Evidence-Based Practice and Nursing Research: Avoiding Confusion